-
[show abstract]
[hide abstract]
ABSTRACT: The main treatment in COPD consists of bronchodilator agents. As the severity of disease increases, combined bronchodilators are preferred in place of single agents. Since there is a weak correlation between well being and spirometric parameters, additional life quality questionnaires are used.
The main aim of this study was to investigate whether different bronchodilator combinations have similar effects on quality of life measures in COPD.
Sixty male patients with COPD were randomized into three groups. After a two-week run-in period, life quality scores were determined using the Turkish version of St George's Respiratory Questionnaire (SGRQ). Group 1 was given ipratropium + theophylline (IP + THEO); Group 2 formoterol + theophylline (FOR + THEO) and Group 3 ipratropium + formoterol (IP + FOR). After a 12-week treatment period, symptom, activity and impact scores were again determined.
When compared with baseline, all component scores and total scores improved significantly (Delta total score: 16, 15 and 17 units in Groups I, II, and III, respectively), but there was no significant change between groups (p > 0.05).
According to these results, combined bronchodilator treatments have a significant effect on life quality in COPD, but the effects were observed to be similar between the three different combinations tested.
Pulmonary Pharmacology & Therapeutics 02/2006; 19(2):101-6. · 2.80 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Bronchodilator therapy is the first step treatment in patients with COPD. The beneficial effects of corticosteroids either in health status or in airway inflammation in COPD have been previously studied. The aim of this study was to evaluate whether adding inhaled corticosteroids to combined bronchodilator therapy has additive clinical and anti-inflammatory effects in COPD patients.
Thirty patients with COPD were included in the study. All patients were receiving inhaled anticholinergic and long-acting beta-2 agonist. Inhaled corticosteroid (budesonide 800 microg daily) was added to their current medications for 12 weeks. Before and after this treatment period, spirometric values and arterial blood gas parameters were determined, blood was drawn for measurement of serum inflammatory markers and sputum was induced.
All patients were male, mean age was 67.7+/-8.7 years and duration of disease was 9.7+/-4.3 years. The induced sputum total cell counts, eosinophil and neutrophil counts decreased with corticosteroid treatment. The induced sputum IL-8 and TNF-alpha levels decreased significantly (IL-8; 835.9+/-217 versus 378.4+/-105 pg/ml, p=0.0001, TNF-alpha; 320.7+/-129 versus 201.3+/-52 pg/ml, p=0.003). Serum inflammatory markers and sputum LTB4 levels did not change with treatment.
These results suggested that the addition of inhaled corticosteroids to combined bronchodilator therapy might have anti-inflammatory effects in patients with COPD.
Pulmonary Pharmacology & Therapeutics 02/2005; 18(6):422-6. · 2.80 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Chronic obstructive pulmonary disease (COPD) is characterised by chronic progressive airway obstruction and inflammation. Only a few studies have evaluated the effects of bronchodilator therapy on airway inflammation in patients with COPD.
The aim of this study was to investigate the effects of different combinations of bronchodilator therapies on airway inflammation in COPD.
Thirty patients with COPD and ten healthy nonsmoker subjects were included in the study. COPD patients were randomly classified into three groups. Groups 1, 2 and 3 were treated with ipratropium bromide plus formoterol (IP + FOR), theophylline plus ipratropium bromide (IP + THEO), and formoterol plus theophylline (FOR + THEO), respectively, for 12 weeks. Pulmonary function tests were performed, blood was drawn for arterial blood gas analyses, and sputum was induced before and after treatment. The induced sputum total and differential cell counts, serum and sputum inflammatory markers including interleukin (IL)-8, tumour necrosis factor (TNF)-alpha and leukotriene (LT)-B4 were measured.
When compared with the control group, total sputum cell counts, number of neutrophils, and sputum and serum inflammatory marker levels were significantly higher in COPD patients. Although there were no statistically significant differences among the groups, inflammatory parameters were found to be significantly reduced in all three treatment groups at the end of treatment. Total cell counts were: 2.4 +/- 0.9 versus 1.28 +/- 0.5 x 10(6)cells/g in the IP + FOR group (p < 0.05), 2.32 +/- 0.4 versus 1.37 +/- 0.6 x 10(6)cells/g in the IP + THEO group (p < 0.05), and 3.05 +/- 1.3 versus 1.6 +/- 0.8 x 10(6)cells/g in the FOR + THEO group (p < 0.05). Sputum IL-8 levels were: 1738.5 +/- 292 versus 848 +/- 262 ng/L in the IP + FOR group (p < 0.05), 1543.2 +/- 378 versus 800.2 +/- 224 ng/L in the IP + THEO group (p < 0.05), and 1561.2 +/- 412 versus 815.7 +/- 259 ng/L in the FOR + THEO group (p < 0.05).
Different combinations of bronchodilator therapies caused significant changes in sputum and blood IL-8, TNF-alpha and LTB4 levels of COPD patients without significantly improving pulmonary function tests or arterial blood gas parameters.
Clinical Drug Investigation 01/2005; 25(7):453-61. · 1.82 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Clarithromycin is an antimicrobial agent that can be used for treatment of chronic obstructive pulmonary disease (COPD) exacerbations with bronchodilator therapy. However, it has also been shown that clarithromycin has antiinflammatory effects by the inhibition of cytokine production.
To evaluate the antiinflammatory effect of clarithromycin on serum and sputum interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 levels in patients with COPD.
Thirty men with mild to moderate COPD were enrolled in this prospective, single-center, double-blind, placebo-controlled study. None of the patients was receiving systemic or inhaled corticosteroids during the study. Subjects received either clarithromycin or placebo for 14 days. Before and after this treatment period, spirometric tests and arterial blood gas analysis were performed, blood was drawn for measurement of serum inflammatory markers, and sputum was induced.
There were no statistically significant differences in baseline clinical or laboratory parameters between the groups. After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001). Similarly, decreases in serum inflammatory markers were found in the clarithromycin group while there was no significant change in the placebo group.
This study demonstrated that the decrease in IL-8 and TNF-alpha levels might be related to the antiinflammatory effect of clarithromycin. Thus, we suggest that the use of clarithromycin in COPD exacerbations may either treat the infection or help control the inflammation. Future studies are needed to determine the clinical significance of these findings.
Annals of Pharmacotherapy 10/2004; 38(9):1400-5. · 2.13 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Withdrawal of corticosteroid is associated with a deterioration of health status in COPD. In this study the aim was to determine whether high dose inhaled corticosteroid improves quality of life in patients with COPD.
In total, 38 male patients with moderate COPD were included in the study. Baseline quality of life scores were determined using a Turkish version of the St George's Respiratory Questionnaire (SGRQ). Patients were randomly divided into two groups. Group 1 consisted of 20 patients who received existing bronchodilator therapy plus inhaled corticosteroid (800 micro g budesonide) for 12 weeks, while 18 patients in group 2 received bronchodilator and placebo. The SGRQ was repeated after the treatment period.
All patients were male and mean age was 67 +/- 8.2 years. Symptom, activity, impact, and total scores were assessed and a difference of four units with treatment was considered to be clinically significant. Total score and activity score were decreased by six units and eight units, respectively, in the placebo group while symptom and impact scores did not change significantly. Total scores and the three component scores improved significantly in the corticosteroid group compared to the placebo group (Deltatotal score: -22 in corticosteroid group, -6 in placebo group, P < 0.01).
Inhaled corticosteroid improved quality of life scores in patients with COPD, without significant improvement in airflow obstruction parameters. Since improvement of health status is one of the important aims in COPD treatment, use of inhaled corticosteroids should be considered from this perspective.
Respirology 08/2004; 9(3):352-5. · 2.42 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Previous studies have revealed the relationship between asthma with obesity and low body mass index (BMI) with chronic obstructive pulmonary disease (COPD). Tumor necrosis factor-alpha (TNF-alpha) is thought to be related with low BMI. The aim of this study was to determine sputum and serum TNF-alpha levels in patients with COPD and asthma and to evaluate whether these parameters had correlation with BMI. Thirty patients with moderate persistent asthma and 26 patients with moderate -severe COPD were included. After BMI values were calculated, sputum was induced by inhalation of hypertonic saline solution and blood was drawn for analysis of serum TNF-alpha levels. There were significant differences in age, serum and sputum TNF-alpha levels between asthma and COPD subjects (Sputum TNF-alpha: asthma; 513 +/- 151 pg/mL-COPD: 333 +/- 126 pg/mL, p< 0.001; Serum TNF-alpha: asthma; 332 +/- 114 pg/mL-COPD: 197 +/- 81 pg/mL, p< 0.001), however there was no difference in BMI (asthma; 28 +/- 5.7-COPD; 26.6 +/- 12.9, p= 0.1). Patients were divided into four categories according to their BMI values as underweight, normal, overweight and obese. In asthmatics; there were 12 (40%) obese and 11 (36%) overweight patients while 9 (34%) of COPD patients were underweight. No significant difference was observed among these four groups according to serum-sputum TNF-alpha and smoking history both in asthmatics and in COPD subjects. While there was no correlation between BMI and serum-sputum TNF-alpha levels, BMI was significantly correlated with both smoking history and duration of disease in COPD patients. As a result, most of the asthmatic patients were described as overweight and obese while no such variation was noted in the COPD patients. The induced sputum TNF-alpha levels has no additional benefit on serum TNF-alpha levels which has already known to be associated with BMI.
Tuberkuloz ve toraks 01/2004; 52(3):256-61.
